Brief: IRLAB Expands Phase IIb/III Study

IRLAB Therapeutics AB

11/07/2022 06:09

July 11 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB EXPANDS PHASE IIB/III PD-LIDS STUDY WITH MESDOPETAM
TO
SUPPORT PHASE III PROGRAM AND EXPECTS COMPLETION OF ENROLLMENT
DURING THE SUMMER

Source text for Eikon:  ID:nMFN8XDSGp 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))